ISUP共识会议:前列腺癌分子生物标志物
国际泌尿病理学会(ISUP)就前列腺癌分子病理召开共识会议,综述了预后、预测和诊断性组织分子标志物的现有证据,并汇总了ISUP成员检测实践的调查结果及工作组推荐。
要点
- 局限期前列腺癌预后标志物如Ki-67标记、PTEN缺失或mRNA基因组特征可辅助判断是否需根治性治疗。
- 晚期疾病中BRCA2缺失介导的DNA修复缺陷或错配修复基因缺陷可提示PARP抑制或免疫检查点阻断的效用。
- 雄激素受体相关标志物或提示小细胞神经内分泌前列腺癌的诊断标志物有助于指导AR信号抑制剂和化疗的使用。
核心结论
- 组织基分子标志物(预后、预测、诊断)可辅助前列腺癌临床治疗选择。
研究设计与样本
- 综述类:检索并总结前列腺癌管理中预后、预测和诊断性组织分子标志物的现有证据,并汇总ISUP成员检测实践调查及2019年共识会议推荐。
主要发现
- 局限期前列腺癌预后标志物包括Ki-67标记、PTEN缺失或mRNA基因组特征。
- 晚期疾病预测标志物包括BRCA2缺失介导的DNA修复缺陷或错配修复基因缺陷。
- 雄激素受体相关标志物或提示小细胞神经内分泌前列腺癌的诊断标志物可指导治疗。
关键数值与推荐
- 局限期预后标志物:Ki-67标记、PTEN缺失或mRNA基因组特征。
- 晚期预测标志物:BRCA2缺失介导的DNA修复缺陷或错配修复基因缺陷。
- 诊断标志物:提示小细胞神经内分泌前列腺癌的雄激素受体相关标志物。
临床怎么用
- 病理医生需了解当前检测选项,以指导前列腺癌分子标志物检测并辅助治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The combined clinical and molecular heterogeneity of prostate cancer necessitates the use of prognostic, predictive, and diagnostic biomarkers to assist the clinician with treatment selection. The pathologist plays a critical role in guiding molecular biomarker testing in prostate cancer and requires a thorough knowledge of the current testing options. In the setting of clinically localized prostate cancer, prognostic biomarkers such as Ki-67 labeling, PTEN loss or mRNA-based genomic signatures can be useful to help determine whether definitive therapy is required. In the setting of advanced disease, predictive biomarkers, such as the presence of DNA repair deficiency mediated by BRCA2 loss or mismatch repair gene defects, may suggest the utility of poly-ADP ribosylase inhibition or immune checkpoint blockade. Finally, androgen receptor-related biomarkers or diagnostic biomarkers indicating the presence of small cell neuroendocrine prostate cancer may help guide the use of androgen receptor signaling inhibitors and chemotherapy. In this review, we examine the current evidence for several prognostic, predictive and diagnostic tissue-based molecular biomarkers in prostate cancer management. For each assay, we summarize a recent survey of the International Society of Urology Pathology (ISUP) members on current testing practices and include recommendations for testing that emerged from the ISUP Working Group on Molecular Pathology of Prostate Cancer and the 2019 Consultation Conference on Molecular Pathology of Urogenital Cancers.
引用
- Lotan TL, Tomlins SA, Bismar TA, et al. Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer. Am J Surg Pathol. 2020. PMID: 32044806. doi:10.1097/PAS.0000000000001450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。